CCA
TEVA icon

Conservest Capital Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Conservest Capital Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-11,692
Closed -$375K – 85
2017
Q1 		$375K Buy
+11,692
New +$399K 0.08% 57

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Conservest Capital Advisors's TEVA Position: Q2 2017 in Review

Conservest Capital Advisors sold out of Teva Pharmaceuticals (TEVA) in Q2 2017, closing a stake of 11,692 shares — an estimated $375K sold.

Conservest Capital Advisors first reported a position in TEVA in Q1 2017 and held it in 1 quarter. The position peaked at $375K in Q1 2017. 648 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

  • Conservest Capital Advisors reported no remaining Teva Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Conservest Capital Advisors sold 11,692 Teva Pharmaceuticals shares in Q2 2017, an estimated $375K.
  • Conservest Capital Advisors first reported a position in Teva Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Conservest Capital Advisors's Teva Pharmaceuticals position peaked at $375K in Q1 2017.
  • 648 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on Conservest Capital Advisors's 13F filing for Q2 2017, filed 6 Jul 2017.